Entera Bio reported $265.9 million in cash and says funds can support its planned osteoporosis study into 2030. The study has not started, and results are expected in the second half of 2028, but the cash gives it time to carry out the plan.
The reported cash is expected to support Entera Bio's operations and planned study into 2030. The study is still being prepared, and results are not expected until the second half of 2028. The cash gives the company time to carry out the plan.
Follow Entera Bio (ENTX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ENTX